Cargando…
Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia
PURPOSE: The aim of this work was to study the influence of solidification of meloxicam (Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer, but no surfactant as a furth...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886534/ https://www.ncbi.nlm.nih.gov/pubmed/31819372 http://dx.doi.org/10.2147/DDDT.S220876 |
_version_ | 1783474889856909312 |
---|---|
author | Bartos, Csaba Ambrus, Rita Katona, Gábor Sovány, Tamás Gáspár, Róbert Márki, Árpád Ducza, Eszter Ivanov, Anita Tömösi, Ferenc Janáky, Tamás Szabó-Révész, Piroska |
author_facet | Bartos, Csaba Ambrus, Rita Katona, Gábor Sovány, Tamás Gáspár, Róbert Márki, Árpád Ducza, Eszter Ivanov, Anita Tömösi, Ferenc Janáky, Tamás Szabó-Révész, Piroska |
author_sort | Bartos, Csaba |
collection | PubMed |
description | PURPOSE: The aim of this work was to study the influence of solidification of meloxicam (Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer, but no surfactant as a further stabilizing agent because the final aim was to produce surfactant-free solid phase products as well. METHODS: The solidified samples produced by fluidization and lyophilization (fluidMel, lyoMel) were examined for particle size, crystallinity, and in vitro release of Mel compared to similar parameters of nanoMel. The products were subjected to an animal experiment using per oral administration to verify their bioavailability. RESULTS: Mel containing (1%) nanoMel sample was produced by wet milling process using an optimized amount of PVA (0.5%) which resulted in 130 nm as mean particle size and a significant reduction in the degree of crystallinity (13.43%) of Mel. The fluidization technique using microcrystalline cellulose (MCC) as carrier resulted in a quick conversion and no significant change in the critical product parameters. The process of lyophilization required a longer operation time, which resulted in the amorphization of the crystalline carrier (trehalose) and the recrystallization of Mel increased its particle size and crystallinity. The fluidMel and lyoMel samples had nearly five-fold higher relative bioavailability than nanoMel application by oral administration. The correlation between in vitro and in vivo studies showed that the fixed Mel nanoparticles on the surface of solid carriers (MCC, trehalose) in both the artificial gastric juice and the stomach of the animals rapidly reached saturation concentration leading to faster dissolution and rapid absorption. CONCLUSION: The solidification of the nanosuspension not only increased the stability of the Mel nanoparticles but also allowed the preparation of surfactant-free compositions with excellent bioavailability which may be an important consideration for certain groups of patients to achieve rapid analgesia. |
format | Online Article Text |
id | pubmed-6886534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68865342019-12-09 Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia Bartos, Csaba Ambrus, Rita Katona, Gábor Sovány, Tamás Gáspár, Róbert Márki, Árpád Ducza, Eszter Ivanov, Anita Tömösi, Ferenc Janáky, Tamás Szabó-Révész, Piroska Drug Des Devel Ther Original Research PURPOSE: The aim of this work was to study the influence of solidification of meloxicam (Mel) containing nanosuspension (nanoMel) on the physical stability and drug bioavailability of the products. The nanoMel sample had poly(vinyl alcohol) (PVA) as a protective polymer, but no surfactant as a further stabilizing agent because the final aim was to produce surfactant-free solid phase products as well. METHODS: The solidified samples produced by fluidization and lyophilization (fluidMel, lyoMel) were examined for particle size, crystallinity, and in vitro release of Mel compared to similar parameters of nanoMel. The products were subjected to an animal experiment using per oral administration to verify their bioavailability. RESULTS: Mel containing (1%) nanoMel sample was produced by wet milling process using an optimized amount of PVA (0.5%) which resulted in 130 nm as mean particle size and a significant reduction in the degree of crystallinity (13.43%) of Mel. The fluidization technique using microcrystalline cellulose (MCC) as carrier resulted in a quick conversion and no significant change in the critical product parameters. The process of lyophilization required a longer operation time, which resulted in the amorphization of the crystalline carrier (trehalose) and the recrystallization of Mel increased its particle size and crystallinity. The fluidMel and lyoMel samples had nearly five-fold higher relative bioavailability than nanoMel application by oral administration. The correlation between in vitro and in vivo studies showed that the fixed Mel nanoparticles on the surface of solid carriers (MCC, trehalose) in both the artificial gastric juice and the stomach of the animals rapidly reached saturation concentration leading to faster dissolution and rapid absorption. CONCLUSION: The solidification of the nanosuspension not only increased the stability of the Mel nanoparticles but also allowed the preparation of surfactant-free compositions with excellent bioavailability which may be an important consideration for certain groups of patients to achieve rapid analgesia. Dove 2019-11-28 /pmc/articles/PMC6886534/ /pubmed/31819372 http://dx.doi.org/10.2147/DDDT.S220876 Text en © 2019 Bartos et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Bartos, Csaba Ambrus, Rita Katona, Gábor Sovány, Tamás Gáspár, Róbert Márki, Árpád Ducza, Eszter Ivanov, Anita Tömösi, Ferenc Janáky, Tamás Szabó-Révész, Piroska Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia |
title | Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia |
title_full | Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia |
title_fullStr | Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia |
title_full_unstemmed | Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia |
title_short | Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia |
title_sort | transformation of meloxicam containing nanosuspension into surfactant-free solid compositions to increase the product stability and drug bioavailability for rapid analgesia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886534/ https://www.ncbi.nlm.nih.gov/pubmed/31819372 http://dx.doi.org/10.2147/DDDT.S220876 |
work_keys_str_mv | AT bartoscsaba transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT ambrusrita transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT katonagabor transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT sovanytamas transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT gasparrobert transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT markiarpad transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT duczaeszter transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT ivanovanita transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT tomosiferenc transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT janakytamas transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia AT szaboreveszpiroska transformationofmeloxicamcontainingnanosuspensionintosurfactantfreesolidcompositionstoincreasetheproductstabilityanddrugbioavailabilityforrapidanalgesia |